Saturday 17 October 2026
Export LBRX’s income statement to Excel — free account
LB Pharmaceuticals Inc
LBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 87.4% and free cash flow fell 579.0%, each against the same quarter a year earlier.
36.74
0.05
+0.14%
Follow LBRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (72.07%) | 0.00% | 0.00% | 0.00% |
+4 more TTM periods Free account |
|
| (47.38%) | (19.80%) | (16.11%) | (17.41%) | ||
ROIC |
(1,304.79%) | (220.57%) | (311.67%) | 0.00% | |
Return on Tangible Assets |
(25.66%) | (10.26%) | (8.33%) | (8.96%) | |
Free Cash Flow per Share |
(2.75) | (1.79) | (4.38) | (3.96) | |
Free Cash Flow |
(82.83) | (50.43) | (35.26) | (23.02) | |
Capital Expenditures |
(0.43) | (0.06) | (0.05) | (0.25) | |
| Other line items | |||||
Cash ROIC |
(12.55%) | (6.78%) | (5.91%) | (3.68%) | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.96 | 1.29 | 1.40 | 0.82 | |
Depreciation/Fixed assets |
0.26 | 0.40 | 0.37 | 0.31 | |
Capex/Depreciation |
(0.77) | (0.10) | (0.09) | (0.50) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.73) | (1.78) | (4.38) | (3.92) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates